Company Overview and News

to your dashboard

Headline News

Cynata Therapeutics wins U.S. patent for stem cell technology

Cynata Therapeutics Ltd (ASX:CYP) has been granted a patent for its proprietary Cymerus™ mesenchymal stem cell technology in the U.S.

Cynata Therapeutics Ltd crosses major milestone in the U.S.

Cynata Therapeutics Ltd (ASX:CYP) has crossed a major milestone by successfully completed the pre-IND (investigational new drug) meeting with the U.S. FDA (Food and Drug Administration).

Glioblastoma Multiforme Pipeline Therapeutics and Drug Profiles Analysis 2017 - RnR Market Research

2017-07-03 prnewswire
Glioblastoma Multiforme Pipeline Therapeutics Development 2017 report provides Companies Involved in Therapeutics Development like AbbVie, Novartis AG, Novogen, Merck KGaA and others. Report encapsulates all the dormant and discontinued Glioblastoma Multiforme pipeline projects.

Cynata Therapeutics achieves progress in stem cell technology

Cynata Therapeutics (ASX:CYP) has received the Notice of Allowance from the U.S. patent office for a patent application tied to its proprietary Cymerus™ stem cell technology.

Regenerative Medicine Market to Grow Over $53.7 Billion by 2021 With 23.3% CAGR Says a Report at

2017-05-17 prnewswire
Global Regenerative Medicine Market Analysis & Forecast to 2021 report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials.

Cynata Therapeutics to reveal details on clinical trial

Cynata Therapeutics (ASX:CYP) has some very interesting news on the horizon, with the company entering an ASX trading halt pending an update on its Phase 1 clinical trial. The halt will remain in place until the opening of trade on Wednesday 17th May 2017, or earlier if an announcement will be made to the market.

Global Regenerative Medicine Market Analysis & Forecast 2017-2021 - Research and Markets

2017-05-05 prnewswire
Research and Markets has announced the addition of the "Global Regenerative Medicine Market Analysis & Forecast to 2021 - Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries" report to their offering.

Cynata Therapeutics: Access latest PPT from Proactive's CEO Sessions

Cynata Therapeutics' (ASX:CYP) CEO, Dr Ross Macdonald, joined Proactive's CEO Sessions in Sydney on Tuesday 14th March and Melbourne on Wednesday 15th March.

Cobalt Blue to outline resource growth strategy at Proactive's CEO Sessions

Cobalt Blue Holdings (ASX:COB) was only recently minted on the ASX, yet the company has already outlined a rapid growth story.

White Cliff Minerals brings gold, lithium, nickel to Proactive's CEO Sessions

White Cliff Minerals (ASX:WCN) has near-term gold production potential, and is currently working towards a new JORC Resource for the high-grade Aucu gold project located in the Kyrgyz Republic of central Asia.

Bluechiip brings wireless tracking technology to Proactive's CEO Sessions

Bluechiip (ASX:BCT) has developed an IT based temperature and identification tracking solution for biosamples in the health and life sciences industry.

Proactive's CEO Spotlight Sessions: Cynata, Bluechiip, White Cliff, Legend Mining

These events are tailor-made for private and professional investors who have exposure to equities, particularly growth stocks - or indeed anyone who is considering putting their money to work in dynamic sectors such as mining, oil and gas, technology and drug discovery.

Cynata Therapeutics talks stem cell research at Proactive's CEO Sessions

Cynata Therapeutics (ASX:CYP) is a stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™.

Legend Mining brings Fraser Range nickel-copper hunt to Proactive's CEO Sessions

Legend Mining (ASX:LEG) is exploring on one of Australia's host post codes, the Fraser Range of Western Australia, with partner Creasy Group.

Cynata Therapeutics secures funds to progress stem cell technology

Furthermore, Cynata expects to receive $4 million towards the end of this month via the issue of shares to FUJIFILM, as part of a strategic partnership.